Scemblix® (Asciminib)

Scemblix® (Asciminib)

SCEMBLIX® (asciminib) tablets is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with 2 or more tyrosine kinase inhibitors (TKIs) and Ph+ CML in CP with the T315I mutation. Learn more below.